Feds make changes to drug patent legislation

Guest Contributor
November 2, 2006

The federal government has introduced changes to the regulations governing patented medicines that is says will strengthen the economy "by restoring certainty, predictability and balance to Canada's intellectual property framework for pharmaceuticals and biopharmaceuticals". Effective October 5/06, the changes to Health Canada regulations extend the period of market exclusivity for new and innovative drugs from five-to-eight years and an additional six months of market exclusivity for drugs that are the subject of pediatric clinical trials. The changes also affect Industry Canada regulations, restoring their "original policy intent" to allow lower-cost, generic versions of innovative drugs to enter the market "immediately following the expiry of relevant patents". Rx&D, the industry association representing Canada's patent-holding pharmaceutical firms, welcomed the changes but expressed concern that "incremental innovation will no longer be fully respected and recognized". The Canadian Generic Pharmaceutical Association (CGPA) countered that the changes will drive up the cost of prescription drugs by as much as $600 million over five years. The CGPA says the legislation limiting incremental changes to drug patents (evergreening) are long overdue and "merely codify a Supreme Court decision" that had already prohibited the practice....


Other News






Events For Leaders in
Science, Tech, Innovation, and Policy


Discuss and learn from those in the know at our virtual and in-person events.



See Upcoming Events










You have 1 free article remaining.
Don't miss out - start your free trial today.

Start your FREE trial    Already a member? Log in






Top

By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.